BACKGROUND: Using surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help differentiate symptomatic effects of potential neuroprotective agents from true disease-modifying effects. A systematic review was undertaken to determine what biomarkers for disease progression in Parkinson's disease (PD) exist. METHODS: MEDLINE and EMBASE (1950-2010) were searched using five search strategies. Abstracts were assessed to identify papers meriting review in ...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- Publisher copy:
- Copyright holder:
- McGhee et al.
- Copyright date:
- © 2013 McGhee et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A systematic review of biomarkers for disease progression in Parkinson's disease.
If you are the owner of this record, you can report an update to it here: Report update to this record